18F-DCFPyL PET/CT in metastatic renal cell carcinoma
GM Currie, M Trifunovic, J Liu, S Kim… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Targeted molecular imaging with PET uses chemical ligands that are peptides specifically
targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially …
targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially …
Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
Objective Molecular imaging with positron emission tomography (PET) provides a powerful
means of identifying and characterizing cancerous processes, as well as providing a …
means of identifying and characterizing cancerous processes, as well as providing a …
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT
Y Yin, SP Campbell, MC Markowski… - Molecular imaging and …, 2019 - Springer
Purpose To investigate the utility of prostate-specific membrane antigen (PSMA)-targeted
[18 F] DCFPyL positron emission tomography (PET)/X-ray computed tomography (CT) …
[18 F] DCFPyL positron emission tomography (PET)/X-ray computed tomography (CT) …
Detection of 18F-FDG PET/CT occult lesions with 18F-DCFPyL PET/CT in a patient with metastatic renal cell carcinoma
Renal cell carcinoma (RCC) is common with more than 60,000 new cases in the United
States yearly. No curative therapies are available for metastatic RCC. Improved methods of …
States yearly. No curative therapies are available for metastatic RCC. Improved methods of …
First-in-man analysis of [18F] DCFPyL, a second generation, 18F-labeled PSMA-targeted radiotracer, in patients with metastatic prostate cancer
E Mena, Z Szabo, S Rowe, E Antonarakis… - 2015 - Soc Nuclear Med
399 Objectives Prostate-specific membrane antigen (PSMA) is highly expressed in prostate
cancer (PC). We previously published the performance of [18 F] DCFBC, the first radio …
cancer (PC). We previously published the performance of [18 F] DCFBC, the first radio …
[PDF][PDF] Urology Case Reports
abstract Radiotracers targeting prostate-specific membrane antigen (PSMA), including [18F]
DCFPyL, have been extensively investigated as a means to image prostate cancer more …
DCFPyL, have been extensively investigated as a means to image prostate cancer more …
Normal organ uptake variability on PSMA-targeted 18F-DCFPyL PET/CT
519 Objectives 18F-DCFPyL is a small-molecule, PSMA-targeted PET radiotracer that
shows promise in the detection of primary and metastatic prostate cancer (PC) lesions. As a …
shows promise in the detection of primary and metastatic prostate cancer (PC) lesions. As a …
PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
SP Rowe, KJ Macura, E Mena, AL Blackford… - Molecular imaging and …, 2016 - Springer
Purpose Current standard of care conventional imaging modalities (CIM) such as X-ray
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …
computed tomography (CT) and bone scan can be limited for detection of metastatic prostate …
Lesion detection with the second generation, 18F-labeled prostate-specific membrane antigen (PSMA)-targeted radiotracer DCFPyL
S Rowe, Z Szabo, K Macura, E Antonarakis… - 2015 - Soc Nuclear Med
453 Objectives A variety of low-molecular weight (LMW) PSMA-targeted PET and SPECT
radiotracers have shown promise for imaging prostate cancer. We report our initial …
radiotracers have shown promise for imaging prostate cancer. We report our initial …
Prospective comparison of PET imaging with PSMA-targeted 18F-DCFPyL versus Na18F for bone lesion detection in patients with metastatic prostate cancer
Bone metastases in prostate cancer (PCa) have important prognostic significance, and
imaging modalities used for PCa staging should have high sensitivity for detecting such …
imaging modalities used for PCa staging should have high sensitivity for detecting such …